ACE and Hypertension: The observed down-regulation of ACE2 by SARS-CoV-2 could suppress that increase in ACE2 levels mediated by ACE-Is and ARBs, thus counteracting their beneficial effects on hypertension and CVD [32], and explaining the poorer clinical outcome observed when these comorbidities are present.